BioSpace News Archive

Medtronic Launches Telescope(TM) Guide Extension Catheter to Support Complex Coronary Cases

FDA Cleared and CE Marked, Telescope Enters Global Market with Design Innovations to Enable Smooth Delivery of Coronary Stents and Balloons

May 16, 2019
·
3 min read
FDA

FDA Approves Combination Treatment for CLL and SLL

The combination of Venclexta and Gazyva was rapidly approved by the FDA under a pilot program.

May 16, 2019
·
2 min read
·
Alex Keown
Policy

$1.1 Billion in Lawsuits Filed Against Opioid Makers in Canada

Purdue, Bristol-Myers Squibb and Apotex have been singled out in opioid-related lawsuits in Canada.

May 16, 2019
·
2 min read
·
Alex Keown
UK’s ICR to Tackle Treatment-Resistant Cancers with “Darwinian” Drug

The Institute of Cancer Research (ICR) in London, UK, is investing an initial £75 million to create a global center in what it is calling anti-evolution therapies for cancer.

May 16, 2019
·
3 min read
·
Mark Terry
Business

BioSpace Movers and Shakers, May 17

Biopharma companies add new leaders to executive roles and boards of directors.

May 16, 2019
·
5 min read
·
Alex Keown
Business

Probiodrug Reports First Quarter 2019 Business Update

Probiodrug AG announced today its first quarter business update for the period ending March 31, 2019.

May 16, 2019
·
6 min read
Pharming Today Celebrates “hae day :-)” – the Global Awareness Day for Hereditary Angioedema, a Rare Life-threatening Condition

Pharming Group N.V. today supports world “hae day :-)”.

May 16, 2019
·
5 min read
Business

GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11

Recognizing the Support of the National Institutes of Health and the

May 16, 2019
·
5 min read
Business

Ginkgo Bioworks Buys Warp Drive Bio’s Genome Mining Platform

Ginkgo Bioworks bought Warp Drive Bio’s genome mining platform, which includes its genome mining team, technology and database.

May 16, 2019
·
3 min read
·
Mark Terry
Drug Development

Agios Pharma’s Tibsovo Shows Positive Results in Phase III for Another Cancer Indication

Agios Pharmaceuticals, headquartered in Cambridge, Mass., announced that its Tibsovo (ivosidenib) hit its primary endpoint in the Phase III ClarIDHy trial in patients with cholangiocarcinoma with an isocitrate dehydrogenase 1 (IDH1) mutation.

May 16, 2019
·
2 min read
·
Mark Terry